ZENTIVA PHARMA UK LIMITED
Get an alert when ZENTIVA PHARMA UK LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-01-14 (in 8mo)
Last made up 2025-12-31
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£8M
-20.8% vs 2023
Employees
52
+6.1% vs 2023
Profit before tax
-£738K
+30.2% vs 2023
Name history
Renamed 5 times since incorporation
- ZENTIVA PHARMA UK LIMITED 2018-07-05 → present
- WINTHROP PHARMACEUTICALS UK LIMITED 2004-12-30 → 2018-07-05
- STERWIN MEDICINES LIMITED 2000-11-01 → 2004-12-30
- SANOFI-SYNTHELABO LIMITED 1999-08-16 → 2000-11-01
- SANOFI PHARMA LTD 1988-05-04 → 1999-08-16
- OPENHEATH LIMITED 1987-08-28 → 1988-05-04
Net assets
2-year trend · vs Consumer Discretionary median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £111,862,000 | £123,456,000 | |
| Operating profit | £2,327,000 | £3,084,000 | |
| Profit before tax | -£1,057,000 | -£738,000 | |
| Net profit | -£2,122,000 | -£2,187,000 | |
| Cash | £20,033,000 | — | |
| Total assets less current liabilities | £49,480,000 | £45,290,000 | |
| Net assets | £10,534,000 | £8,347,000 | |
| Equity | £10,534,000 | £8,347,000 | |
| Average employees | 49 | 52 | |
| Wages | £4,445,000 | £4,587,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 2.1% | 2.5% | |
| Net margin | -1.9% | -1.8% | |
| Return on capital employed | 4.7% | 6.8% | |
| Gearing (liabilities / total assets) | 87.9% | 91.1% | |
| Current ratio | 1.95x | 1.71x | |
| Interest cover | 0.54x | 0.50x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“After considering these forecasts and the financial and operational ability of the Group to continue as a going concern, the directors expect that the Company will have access to adequate resources to continue in operational existence for the period to 30 June 2026. Accordingly, they continue to adopt the going concern basis in preparing the annual report and financial statements.”
Significant events
- “With the closure of the 2019 VPAS Branded Medicines Tax scheme, the Company adopted the 2024 Voluntary VPAG scheme and has worked on initiatives to ensure a robust accrual method to capture costs associated with the new scheme.”
- “The Company also renewed its logistics partner agreement with Alloga, securing the Company's distribution chain.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 26 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| KNIGHT, Anthony Daniel | Director | 2020-09-09 | Mar 1969 | British |
| QUIN, Sophie | Director | 2022-08-09 | Feb 1980 | British |
Show 26 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| MCCLELLAN, Michael James | Secretary | 2008-02-13 | 2010-05-12 |
| ROBERTS, Helen | Secretary | 2001-01-02 | 2008-01-30 |
| THUILLIEZ, Gordon Dennis | Secretary | 1996-06-30 | 2000-01-02 |
| WARNOCK-SMITH, Anthony | Secretary | — | 1996-06-30 |
| BEWS, Susan Mary Maud, Dr | Director | — | 1998-12-24 |
| BROOKSBY, Nigel Stanley | Director | 1996-06-30 | 2010-05-12 |
| DARK, Blake Alexander Richard | Director | 2005-02-28 | 2007-11-16 |
| DE FORCEVILLE, Guillaume Adrien | Director | 2004-11-08 | 2007-11-16 |
| DUHALDE, Francois-Xavier | Director | 2016-04-01 | 2018-09-21 |
| FRY, Hugo Rupert Alexander | Director | 2017-01-01 | 2018-09-21 |
| GOURLET, Christophe | Director | 2001-01-02 | 2003-04-01 |
| HART, Luke Ingmire | Director | 2019-07-15 | 2023-01-22 |
| HILL, Jane | Director | 2019-02-01 | 2020-11-30 |
| JACOB, Etienne Marie Charles Robert | Director | 2004-11-08 | 2006-12-31 |
| KHANDELWAL, Manish | Director | 2018-09-21 | 2019-09-02 |
| KING, Eric | Director | 2001-01-02 | 2005-02-28 |
| MCCLELLAN, Michael James | Director | 2007-11-16 | 2010-10-01 |
| OLDFIELD, Stephen Philip | Director | 2010-05-12 | 2014-07-25 |
| PROSSER, Andrew Michael James | Director | 2010-09-01 | 2016-04-01 |
| SELL, Piret | Director | 2018-09-21 | 2019-02-01 |
| STENVALL, Tarja Johanna | Director | 2014-11-19 | 2016-09-30 |
| THIBERGE, Olivier Alain | Director | 2001-01-02 | 2002-10-31 |
| THUILLIEZ, Gordon Dennis | Director | 1998-12-24 | 2000-01-02 |
| VERNIER, Thierry | Director | 2003-04-01 | 2004-11-08 |
| WARNOCK-SMITH, Anthony | Director | — | 1996-06-30 |
| WODDIS, Paul | Director | — | 1994-06-28 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Ai Sirona (Luxembourg ) Limited | Corporate entity | Shares 75–100% | 2019-09-01 | Ceased 2019-09-01 |
| Ai Sirona (Luxembourg ) Limited | Corporate entity | Shares 75–100% | 2019-09-01 | Active |
| Ai Sirona (Luxembourg) Acquisition S.A.R.L. | Corporate entity | Shares 75–100% | 2018-09-30 | Ceased 2018-09-30 |
| Aventis Pharma Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2018-09-30 |
Filing timeline
Last 20 of 203 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-01-07 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-01-07 | AD02 | address | Change sail address company with old address new address | |
| 2025-07-14 | AA | accounts | Accounts with accounts type full | |
| 2025-01-31 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-25 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2024-10-16 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2024-09-11 | AA | accounts | Accounts with accounts type full | |
| 2024-07-16 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2024-02-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-11-07 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2023-08-25 | AA | accounts | Accounts with accounts type full | |
| 2023-01-31 | TM01 | officers | Termination director company with name termination date | |
| 2023-01-13 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-08-23 | AP01 | officers | Appoint person director company with name date | |
| 2022-06-27 | AA | accounts | Accounts with accounts type full | |
| 2022-02-04 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2021-09-07 | AA | accounts | Accounts with accounts type full | |
| 2021-03-31 | SH01 | capital | Capital allotment shares | |
| 2021-03-30 | SH01 | capital | Capital allotment shares | |
| 2021-03-09 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+10.4%
£111,862,000 £123,456,000
-
Cash
—
Not reported
-
Net assets
-20.8%
£10,534,000 £8,347,000
-
Employees
+6.1%
49 52
-
Operating profit
+32.5%
£2,327,000 £3,084,000
-
Profit before tax
+30.2%
-£1,057,000 -£738,000
-
Wages
+3.2%
£4,445,000 £4,587,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers